SalvePeds: An early-stage pharmaceutical company offering the novel drug ND-336 as a topical therapy for the treatment of diabetic foot ulcers. SalvePeds’ goal is to provide an effective, safe and convenient therapeutic treatment for DFUs to improve the quality of life for patients and ultimately decrease the number of ulcer related amputations. (University of Notre Dame) … from Inside Indiana Business